Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.
Journal article published in 2015 by
L. Manso,
D. Torregrosa,
I. Álvarez,
Palomo Ag,
R. Pérez Carrión,
J. Cassinello,
I. Gallegos Sancho,
I. Chacón López Muñiz,
C. Olier,
R. Llorente,
A. Fernández Aramburo,
C. Llorca,
E. Gálve,
X. González 
,
C. Bueno
and other authors.
,
C. Bueno
and other authors.
